MDCX Medicus Pharma Ltd
Price Chart
Executive Summary
Medicus Pharma (MDCX) released updated topline data from its Phase 2 SKNJCT-003 trial showing 73% clinical clearance and 40% histological clearance in the 200-µg cohort for its SkinJect® microneedle therapy in basal cell carcinoma (BCC). The results demonstrate a clear separation from the active placebo arm (38%), supporting both device-mediated biological activity and additional drug effect. The company plans to advance regulatory discussions with the FDA and pursue strategic partnerships.
Actionable Insight
Traders should monitor upcoming FDA engagement and potential partnership announcements as near-term catalysts. The 73% clinical clearance rate is strong for a non-surgical modality and may attract dermatology or oncology-focused biotech partners. Consider positioning ahead of EOP2 meeting in H1 2026.
Key Facts
- Phase 2 SKNJCT-003 trial showed 73% clinical clearance and 40% histological clearance in the 200-µg D-MNA cohort at Day 57
- Active placebo (P-MNA) arm showed 38% clinical clearance, demonstrating device-mediated biological activity
- Clear separation between treatment (73%) and placebo (38%) supports therapeutic contribution of D-MNA
- Company plans End-of-Phase-2 meeting with FDA in first half of 2026
- Data considered 'decision-grade' for advancing regulatory and partnering discussions
- SkinJect targets non-surgical treatment for BCC, particularly impactful for Gorlin Syndrome patients
Financial Impact
Potential significant upside due to de-risking of clinical program; no direct revenue or EPS impact yet
Risk Factors
- Phase 2 data may not translate to Phase 3 success
- FDA may require larger or longer trials for approval
- Histological clearance (40%) lags clinical clearance, raising questions about durability
- No guaranteed partnership or commercialization path despite 'decision-grade' characterization
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251726 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
29d ago
|
Press Release
| $0.3010 $0.3000 | ▲ +0.33% | ▲ +1.30% | $0.3380 (−12.29%) |
|
May 6, 2026
5w ago
|
Press Release
| $0.3330 $0.3150 | ▼ −5.41% | ▼ −6.54% | $0.3380 (+1.50%) |
|
Apr 6, 2026
9w ago
|
Press Release
| $0.4910 $0.4020 | ▼ −18.13% | ▼ −22.26% | $0.3380 (−31.16%) |
|
Apr 1, 2026
10w ago
|
Press Release
| $0.4200 $0.4420 | ▲ +5.24% | ▲ +1.47% | $0.3380 (−19.52%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $0.5240 $0.5000 | ▼ −4.58% | ▼ −2.54% | $0.3380 (−35.50%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $0.5200 $0.5240 | ▲ +0.77% | ▲ +2.12% | $0.3380 (−35.00%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $0.6780 $0.5000 | ▼ −26.25% | ▼ −24.02% | $0.3380 (−50.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access